Compare · CWBR vs NTLA
CWBR vs NTLA
Side-by-side comparison of CohBar Inc. (CWBR) and Intellia Therapeutics Inc. (NTLA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CWBR and NTLA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NTLA is the larger of the two at $2.20B, about 79.8x CWBR ($27.6M).
- NTLA has hit the wire 12 times in the past 4 weeks while CWBR has been quiet.
- NTLA has more recent analyst coverage (25 ratings vs 1 for CWBR).
- Company
- CohBar Inc.
- Intellia Therapeutics Inc.
- Price
- $0.95+7.66%
- $15.76+0.61%
- Market cap
- $27.6M
- $2.20B
- 1M return
- -
- +28.51%
- 1Y return
- -
- +70.51%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2016
- News (4w)
- 0
- 12
- Recent ratings
- 1
- 25
CohBar Inc.
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, acute respiratory distress syndrome, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial-derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases, CB5064 analogs for COVID-19 associated ARDS, MBT5 analogs for CXCR4-related cancer and orphan diseases, and MBT3 analogs for cancer immunotherapy. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
Intellia Therapeutics Inc.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Latest CWBR
- SEC Form 25-NSE filed by CohBar Inc.
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Why SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
- CohBar, Inc.: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (Form 8-K)
- CohBar Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- CohBar Inc. filed SEC Form 8-K: Leadership Update, Other Events
- Why CohBar (CWBR) Stock Is Down Nearly 50% Today
- Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Latest NTLA
- Intellia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
- Director Verwiel Frank was granted 9,200 shares, increasing direct ownership by 35% to 35,148 units (SEC Form 4)
- Director Keresty Georgia was granted 9,200 shares, increasing direct ownership by 29% to 41,083 units (SEC Form 4)
- Director Goodman Jesse was granted 9,200 shares, increasing direct ownership by 38% to 33,559 units (SEC Form 4)
- Director Goff Brian was granted 9,200 shares, increasing direct ownership by 39% to 32,609 units (SEC Form 4)
- Director Cohen Fred E was granted 9,200 shares, increasing direct ownership by 4% to 216,653 units (SEC Form 4)
- Director Chase William J was granted 9,200 shares, increasing direct ownership by 7% to 143,893 units (SEC Form 4)
- Director Bhanji Muna was granted 9,200 shares, increasing direct ownership by 34% to 36,403 units (SEC Form 4)
- Intellia Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders